| Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. | |
| | |
MedLine Citation:
|
PMID: 21105985 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: • To evaluate the consequences on male sexual function of intraprostatic injection of botulinum toxin type A (BoNT/A) as a treatment for benign prostatic hyperplasia (BPH). Although BoNT/A is effective in decreasing symptoms of BPH, neuronal impairment caused by the neurotoxin might affect emission/ejaculation. These aspects have not been evaluated before. PATIENTS AND METHODS: • In all, 16 sexually active men aged >60 years with BPH/benign prostatic enlargement (BPE), International Prostate Symptom Score (IPSS) ≥8 and a maximum urinary flow rate (Q(max)) <15 mL/s refractory to standard medical therapy volunteered for the study. • Patients were injected transrectally, under ultrasonographic control, with 200 U of BoNT/A in the prostate. Evaluation was carried out at baseline and 1, 3 and 6 months post-treatment. Erectile function was evaluated using the International Index of Erectile Function - Short Form (IIEF-5) questionnaire. • Orgasmic/ejaculatory function and libido were evaluated using questions 9, 10, 11 and 12 of the IIEF - Long Form. Total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin were also investigated. RESULTS: • The mean age was 73 ± 6 years. The IIEF-5 score was 16.5 ± 6 at baseline, 15.7 ± 6 at 1 month, 16.6 ± 6 at 3 months and 15.7 ± 5 at 6 months (differences nonsignificant). • The score for ejaculatory/orgasmic function (questions 9 and 10) remained fairly constant from baseline to the sixth month, 8.3 ± 1.9 and 8 ± 2.1 respectively. • The sexual desire score (questions 11 and 12 of the IIEF) also remained little changed from baseline (5.9 ± 1.6) to month 6 (6.1 ± 2). Total serum testosterone, LH, FSH and prolactin did not change during the study. CONCLUSIONS: • Intraprostatic injection of BoNT/A in patients with BPE does not impair erectile, orgasmic or ejaculatory functions and does not change libido. • The male hormonal profile is not altered by BoNT/A injection. This facilitates the acceptance of BoNT/A as a treatment for BPH/BPE lower urinary tract symptoms (LUTS) refractory to standard medical management. |
| | |
Authors:
|
João Silva; Rui Pinto; Tiago Carvalho; Francisco Botelho; Pedro Silva; Carlos Silva; Francisco Cruz; Paulo Dinis |
Related Documents
:
|
15801365 - Photoselective ktp laser vaporization of the prostate: first experiences with 65 proced... 18502565 - Functional outcome following photoselective vaporisation of the prostate (pvp): urodyna... 11904315 - Quality of life following localized prostate cancer treated initially with androgen dep... 15538235 - Transperitoneal or extraperitoneal laparoscopic radical prostatectomy: does the approac... 12525715 - Neutralizing antibodies during treatment of secondary progressive ms with interferon be... 18586905 - Initial experience with the pascal photocoagulator: a pilot study of 75 procedures. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-11-24 |
Journal Detail:
|
Title: BJU international Volume: 107 ISSN: 1464-410X ISO Abbreviation: BJU Int. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-31 Completed Date: 2011-08-01 Revised Date: 2012-10-09 |
Medline Journal Info:
|
Nlm Unique ID: 100886721 Medline TA: BJU Int Country: England |
Other Details:
|
Languages: eng Pagination: 1950-4 Citation Subset: IM |
Copyright Information:
|
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL. |
Affiliation:
|
Department of Urology, Hospital S. João, Institute for Molecular and Cell Biology, Porto, Portugal. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Botulinum Toxins, Type A / adverse effects, therapeutic use* Cohort Studies Ejaculation / drug effects Humans Libido / drug effects Male Neurotoxins / adverse effects, therapeutic use* Orgasm / drug effects Penile Erection / drug effects Prostatic Hyperplasia / drug therapy* Sexual Behavior / drug effects* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Neurotoxins; EC 3.4.24.69/Botulinum Toxins, Type A |
| Comments/Corrections | |
Comment In:
|
J Urol. 2012 Sep;188(3):907
[PMID:
22883794
]
J Urol. 2012 Jun;187(6):2160-1 [PMID: 22579196 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plasmodium salvages cholesterol internalized by LDL and synthesized de novo in the liver.
Next Document: Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclo...